Stroke Center, Department of Neurology, the First Hospital of Jilin University, Changchun, China.
Department of Neurology, the First Hospital of Jilin University, Changchun, China.
BMC Med. 2024 Oct 3;22(1):304. doi: 10.1186/s12916-024-03517-6.
S100β is a biomarker of astroglial damage, the level of which is significantly increased following brain injury. However, the characteristics of S100β and its association with prognosis in patients with acute ischemic stroke following intravenous thrombolysis (IVT) remain unclear.
Patients in this multicenter prospective cohort study were prospectively and consecutively recruited from 16 centers. Serum S100β levels were measured 24 h after IVT. National Institutes of Health Stroke Scale (NIHSS) and hemorrhagic transformation (HT) were measured simultaneously. NIHSS at 7 days after stroke, final infarct volume, and modified Rankin Scale (mRS) scores at 90 days were also collected. An mRS score ≥ 2 at 90 days was defined as an unfavorable outcome.
A total of 1072 patients were included in the analysis. The highest S100β levels (> 0.20 ng/mL) correlated independently with HT and higher NIHSS at 24 h, higher NIHSS at 7 days, larger final infarct volume, and unfavorable outcome at 3 months. The patients were divided into two groups based on dominant and non-dominant stroke hemispheres. The highest S100β level was similarly associated with the infarct volume in patients with stroke in either hemisphere (dominant: β 36.853, 95% confidence interval (CI) 22.659-51.048, P < 0.001; non-dominant: β 23.645, 95% CI 10.774-36.516, P = 0.007). However, serum S100β levels at 24 h were more strongly associated with NIHSS scores at 24 h and 3-month unfavorable outcome in patients with dominant hemisphere stroke (NIHSS: β 3.470, 95% CI 2.392-4.548, P < 0.001; 3-month outcome: odds ratio (OR) 5.436, 95% CI 2.936-10.064, P < 0.001) than in those with non-dominant hemisphere stroke (NIHSS: β 0.326, 95% CI - 0.735-1.387, P = 0.547; 3-month outcome: OR 0.882, 95% CI 0.538-1.445, P = 0.619). The association of S100β levels and HT was not significant in either stroke lateralization group.
Serum S100β levels 24 h after IVT were independently associated with HT, infarct volume, and prognosis in patients with IVT, which suggests the application value of serum S100β in judging the degree of disease and predicting prognosis.
S100β 是星形胶质细胞损伤的生物标志物,脑损伤后其水平显著升高。然而,静脉溶栓(IVT)后 S100β 的特征及其与预后的关系仍不清楚。
本多中心前瞻性队列研究纳入了 16 个中心的连续患者。在 IVT 后 24 小时测量血清 S100β 水平。同时测量国立卫生研究院卒中量表(NIHSS)和出血转化(HT)。还收集了卒中后 7 天的 NIHSS、最终梗死体积和 90 天的改良 Rankin 量表(mRS)评分。90 天时 mRS 评分≥2 定义为不良结局。
共纳入 1072 例患者。最高 S100β 水平(>0.20ng/mL)与 HT 及 24 小时 NIHSS 升高、7 天 NIHSS 升高、最终梗死体积较大以及 3 个月不良预后独立相关。根据优势半球和非优势半球卒中,将患者分为两组。最高 S100β 水平与两侧半球卒中患者的梗死体积均相关(优势半球:β36.853,95%置信区间(CI)22.659-51.048,P<0.001;非优势半球:β23.645,95%CI 10.774-36.516,P=0.007)。然而,24 小时血清 S100β 水平与优势半球卒中患者 24 小时 NIHSS 评分和 3 个月不良结局的相关性更强(NIHSS:β3.470,95%CI 2.392-4.548,P<0.001;3 个月结局:比值比(OR)5.436,95%CI 2.936-10.064,P<0.001),而非优势半球卒中患者(NIHSS:β0.326,95%CI-0.735-1.387,P=0.547;3 个月结局:OR 0.882,95%CI 0.538-1.445,P=0.619)。在两组卒中侧化患者中,S100β 水平与 HT 无显著相关性。
IVT 后 24 小时血清 S100β 水平与 HT、梗死体积和 IVT 患者的预后独立相关,提示血清 S100β 在判断疾病严重程度和预测预后方面具有应用价值。